MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma

Inclusion Criteria

• •In order to be eligible for this study, a subject must meet all of the following criteria:
• •Histologically confirmed squamous cell carcinoma of the esophagus or GE- junction (Siewert I/II)
• •Potentially resectable, locally advanced esophageal tumor (cT1bN+, cT2-3, N0-3, M0) based on standard primary staging by EUS and 18F-FDG PET-CT
• •Scheduled to receive neoadjuvant chemoradiotherapy according to CROSS-regimen: weekly administration of carboplatin and paclitaxel for 5 weeks and concurrent radiotherapy (41.4Gy in 23 fractions, 5 days per week), followed by esophagectomy (as judged by the multidisciplinary tumor board)
• •Tumor length ≤ 10 cm
• •Age ≥ 18 years
• •WHO performance status 0-2
• •Signed informed consent
• •Tumor volume that can be defined on MRI at baseline (T2w and DW-MRI)
• •Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.